GIG
GIG, one of the leading healthcare investment institute, was founded in Shenzhen in 2001. AUM is RMB ¥20b. It has invested in 80+ healthcare companies. 22 went IPO. GIG has 90+ staff in team with operating offices in Shenzhen, Shanghai, Beijing, Nanjing and Hongkong.
Denise Chen
PartnerMaryland Department of Commerce
- As one of the nation’s largest and fastest growing biotechnology clusters, Maryland is #1 in Ph.D. concentration in biological fields, employed doctoral scientists, and was recognized last year at the 4th best biotechnology cluster in the nation by Genetic Engineering and Biotechnology News.
- We have facilitated access to 74 Federal laboratories, including the National Institutes of Health, the National Institute for Standards and Technology, the Food and Drug Administration, and the Walter Reed Army Institute of Research.
- We can reach 80% of the U.S. pharmaceutical industry and four nearby international airports to enable efficient travel.
- Maryland’s Cost of Doing Business Index is 16%, 12%, and 10% lower than in Boston, New Jersey, and California, respectively, according to Moody’s Analytics Regional Financial Review. In our industry, that translates to a lower cost of operations and wet lab space.
- The cost of living in Maryland can be up to one-and-a-half times lower than in the metropolitan areas of New York, Boston, and San Francisco, according to the Council for Community and Economic Research.
Felicia Pullam
Regional Manager, Asia
Regulaxis
Regulaxis SAS is a French biotech company created in 2013 to develop innovative therapies for human clinic based on new synthetic peptides regulating cell growth and differentiation.
Regulaxis is specialized in the regulation of cell proliferation and/or cell differentiation. The potential therapeutic applications covered by our patents are very broad, especially in the areas of joint/bone or nerve cell regeneration, but also in cancer and related metabolic diseases (diabetes, obesity …).
Our mission is to grant licenses of innovative molecules in a pharmaceutical company after completion of phase II clinical proof of concept.
Regulaxis is strategically focused only on high unmet medical needs but has elected as its first priority:
regeneration of articular cartilage using intra-articular injections of its lead candidate REG-O3.